Roche Pharma Unveils Pan Tumor Liquid Biopsy Test In India

Mumbai: Roche Products (India) Pvt. Ltd. (Roche Pharma India) has recently announced the launch of FoundationOneLiquid CDx, Foundation Medicine's comprehensive pan-tumor liquid biopsy test for patients with solid tumors in India. US FDA approved the FoundationOneLiquid CDx, a comprehensive genomic profiling (CGP) test on August 26. This is the first test that can analyze more than 300 genes and multiple genomic signatures to optimize patient care.
Cancer is a disease of the genome. Most tumors harbor a constellation of genomic alterations that may dictate their clinical behavior and treatment response. Blood-based biomarker testing options like FoundationOneLiquid CDx can help expand access to genomic insights in patients with advanced cancer as compared to a tissue biopsy, which may not be an option for many patients due to reasons such as tumor location and patient's health status.
FoundationOneLiquid CDx is a single non-invasive test based on Next Generation Sequencing technology that gives access to genomic information of over 300 genes. Additionally, the report also provides information about the biomarker signatures microsatellite instability (MSI), and blood tumor mutational burden (bTMB) to support informed decision making for targeted and immunotherapies. "Roche has always been committed to provide best-in-class solutions to serve the needs of cancer patients globally as well as in India. We believe that cancer patients in our country and their physicians deserve the highest quality genomic testing to guide personalized treatment decisions. We are delighted to make this test now available for Indian patients, post US-FDA approval." said Mr. V. Simpson Emmanuel, Managing Director, Roche Pharma India.
Elucidating the nature of the genomic alterations has led to an increase in discovery of many targeted therapy options for patients in recent years. It is becoming increasingly important to provide personalised treatment options to the patients as it has an unprecedented scope in changing the paradigm of cancer care in the future. "US FDA approved FoundationOneLiquid CDx is a comprehensive genomic profiling test that reports genomic alteration results of more than 300 genes, including genomic signatures such as blood tumor mutational burden (bTMB) and microsatellite instability (MSI), as well as all NTRK fusions* for any solid tumor with a single blood draw. It will enable more rapid and informed treatment decisions at the point of care." said Dr. Bruno Jolain, Director - Medical, Roche Pharma India.

Source:https://medicaldialogues.in/news/industry/pharma/roche-pharma-unveils-pan-tumor-liquid-biopsy-test-in-india-71586

Comments

Popular posts from this blog

EMA validates Incyte’s MAA for retifanlimab to treat metastatic squamous cell anal carcinoma

Merck’s Keytruda plus platinum- and fluoropyrimidine-based chemotherapy receives US FDA nod to treat certain patients with locally advanced/metastatic esophageal or GEJ carcinoma

Tumour-targeting drug paves way for bone cancer treatment